Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | AdvanTIG-202: tislelizumab ± ociperlimab in recurrent/metastatic cervical cancer

Jung-Yun Lee, MD, PhD, Yonsei Cancer Hospital, Seoul, South Korea, provides an overview of the AdvanTIG-202 (NCT04693234) trial investigating the efficacy and safety of using tislelizumab, an anti-PD-1 monoclonal antibody (mAb), in combination with or without ociperlimab, an anti-TIGIT mAb, in patients with relapsed recurrent/metastatic (R/M) cervical cancer (CC). In the first stage, 80 patients were randomized into two groups, with one group receiving both TIS and OCI and the other receiving TIS alone. Results from this stage showed an objective response rate (ORR) of 22.5%, including 13 complete responses. Notably, 76.8% of patients had responses lasting at least 6 months. The ORR was higher in patients with PD-L1+ tumors (PD-L1 score ≥5%), reaching 26.2%. Adverse events were observed in around 67% of patients, with only 13% experiencing grade 3 adverse events. The study demonstrated a significant improvement in ORR compared to historical controls for anti-PD-1 therapy. The results from the TIS monotherapy group (C2) were not provided due to limited enrollment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.